Adial Pharmaceuticals Approves Equity Plans at 2026 Annual Meeting

What Happened

• Adial Pharmaceuticals, Inc. (ADIL) convened its 2026 Annual Meeting of Stockholders on September 17, 2026 and filed a Form 8-K reporting the meeting. At the meeting, stockholders approved three equity-related proposals: (i) Amendment No. 8 to the 2017 Equity Incentive Plan to increase the number of shares authorized for issuance, (ii) the Adial Pharmaceuticals, Inc. 2026 Equity Incentive Plan, and (iii) the Adial Pharmaceuticals, Inc. 2026 Employee Stock Purchase Plan (2026 ESPP). The company’s definitive proxy statement for the meeting was filed with the SEC on August 24, 2026, and the full plan documents are attached to the 8-K as Exhibits 10.1–10.3.

Key Details

• Annual meeting date: September 17, 2026.
• Approved items: Amendment No. 8 to the 2017 Equity Incentive Plan (increases shares authorized), the 2026 Equity Incentive Plan, and the 2026 ESPP.
• Proxy filing: Definitive Proxy Statement filed with the SEC on August 24, 2026.
• Exhibits: Full texts of the 2017 Plan amendment and the new 2026 equity and ESPP plans are attached as Exhibits 10.1, 10.2 and 10.3 to the Form 8-K.

Why It Matters

• These approvals give Adial formal authority to grant additional equity awards and offer employee stock purchase benefits, which the company can use for employee compensation, recruiting and retention. For investors, the actions can lead to future share dilution depending on how many awards are issued; the filing does not state specific share counts in this summary but provides the full plan documents as exhibits. The proxy and attached plans are the authoritative sources for detailed terms and any limits on share issuance.